Mesoporous Silica Nanoparticles With Customized Drug Ratio/Loading for Effective Treatment of Gemcitabine‐Resistant Pancreatic Tumors

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a 5‐year survival rate below 13% and limited treatment options due to rapid metastasis and pronounced chemoresistance. Gemcitabine (Gem) remains a first‐line chemotherapy agent; however, its clinical efficacy is hindered...

詳細記述

書誌詳細

主要な著者:	Tamanna Binte Huq, Sudip Kumar Dam, Doaha Awad, Punnya Anil Kumar Jeeja, Farzana Ferdous, Juan L. Vivero‐Escoto
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley-VCH 2026-07-01
シリーズ:	Advanced NanoBiomed Research
主題:	combination therapy controlled release gemcitabine resistance mesoporous silica nanoparticles pancreatic cancer
オンライン･アクセス:	https://doi.org/10.1002/anbr.202500255
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!